XML 36 R25.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Business segment information (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2018
Segment Reporting [Abstract] |
Schedule Of Net Sales by Reporting Segment | The tables below present net sales, which includes product sales and marketing service fees, by reporting segment:
|  | Three Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2018 |  |  | 2017 |  |  | Change |
Bone Growth Therapies |  | $ | 48,059 |  |  | $ | 44,427 |  |  |  | 8.2 | %
Spinal Implants |  |  | 22,102 |  |  |  | 20,155 |  |  |  | 9.7 | %
Biologics |  |  | 14,636 |  |  |  | 15,218 |  |  |  | -3.8 | %
Orthofix Extremities |  |  | 26,911 |  |  |  | 25,447 |  |  |  | 5.8 | %
Net sales |  | $ | 111,708 |  |  | $ | 105,247 |  |  |  | 6.1 | %
|  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2018 |  |  | 2017 |  |  | Change |
Bone Growth Therapies |  | $ | 142,433 |  |  | $ | 136,140 |  |  |  | 4.6 | %
Spinal Implants |  |  | 66,689 |  |  |  | 60,782 |  |  |  | 9.7 | %
Biologics |  |  | 43,639 |  |  |  | 45,866 |  |  |  | -4.9 | %
Orthofix Extremities |  |  | 79,203 |  |  |  | 74,139 |  |  |  | 6.8 | %
Net sales |  | $ | 331,964 |  |  | $ | 316,927 |  |  |  | 4.7 | %
Summary of Non-GAAP Net Margin by Reporting Segment | The table below presents non-GA AP net margin by reporting segment:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2018 |  |  | 2017 |  |  | 2018 |  |  | 2017 |
Bone Growth Therapies |  | $ | 21,151 |  |  | $ | 18,285 |  |  | $ | 61,395 |  |  | $ | 54,887 |
Spinal Implants |  |  | 1,812 |  |  |  | 2,122 |  |  |  | 5,960 |  |  |  | 6,825 |
Biologics |  |  | 6,654 |  |  |  | 6,010 |  |  |  | 18,981 |  |  |  | 18,651 |
Orthofix Extremities |  |  | 8,295 |  |  |  | 7,723 |  |  |  | 23,455 |  |  |  | 20,901 |
Corporate |  |  | (122 | ) |  |  | (103 | ) |  |  | (524 | ) |  |  | (308 | )
Non-GAAP net margin |  | $ | 37,790 |  |  | $ | 34,037 |  |  | $ | 109,267 |  |  | $ | 100,956 |
General and administrative |  |  | 22,705 |  |  |  | 18,068 |  |  |  | 64,457 |  |  |  | 56,759 |
Research and development |  |  | 9,598 |  |  |  | 6,935 |  |  |  | 24,426 |  |  |  | 21,246 |
Changes in fair value of contingent consideration |  |  | 1,580 |  |  |  | — |  |  |  | 2,689 |  |  |  | — |
Operating income |  | $ | 3,907 |  |  | $ | 9,034 |  |  | $ | 17,695 |  |  | $ | 22,951 |
Interest income (expense), net |  |  | (181 | ) |  |  | (15 | ) |  |  | (615 | ) |  |  | 106 |
Other income (expense), net |  |  | (5,054 | ) |  |  | 479 |  |  |  | (5,785 | ) |  |  | (3,284 | )
Income (loss) before income taxes |  | $ | (1,328 | ) |  | $ | 9,498 |  |  | $ | 11,295 |  |  | $ | 19,773 |
Summary of Net Sales by Geographic Destination for Each Reporting Unit | Geographical information The table below present net sales by geographic destination for each reporting unit and for the consolidated Company:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2018 |  |  | 2017 |  |  | 2018 |  |  | 2017 |
Bone Growth Therapies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $ | 48,039 |  |  | $ | 44,427 |  |  | $ | 142,378 |  |  | $ | 136,128 |
International |  |  | 20 |  |  |  | — |  |  |  | 55 |  |  |  | 12 |
Total Bone Growth Therapies |  |  | 48,059 |  |  |  | 44,427 |  |  |  | 142,433 |  |  |  | 136,140 |
Spinal Implants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 16,829 |  |  |  | 17,085 |  |  |  | 53,261 |  |  |  | 51,170 |
International |  |  | 5,273 |  |  |  | 3,070 |  |  |  | 13,428 |  |  |  | 9,612 |
Total Spinal Implants |  |  | 22,102 |  |  |  | 20,155 |  |  |  | 66,689 |  |  |  | 60,782 |
Biologics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 14,634 |  |  |  | 15,202 |  |  |  | 43,623 |  |  |  | 45,816 |
International |  |  | 2 |  |  |  | 16 |  |  |  | 16 |  |  |  | 50 |
Total Biologics |  |  | 14,636 |  |  |  | 15,218 |  |  |  | 43,639 |  |  |  | 45,866 |
Orthofix Extremities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 7,254 |  |  |  | 6,804 |  |  |  | 21,193 |  |  |  | 20,124 |
International |  |  | 19,657 |  |  |  | 18,643 |  |  |  | 58,010 |  |  |  | 54,015 |
Total Orthofix Extremities |  |  | 26,911 |  |  |  | 25,447 |  |  |  | 79,203 |  |  |  | 74,139 |
Consolidated |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 86,756 |  |  |  | 83,518 |  |  |  | 260,455 |  |  |  | 253,238 |
International |  |  | 24,952 |  |  |  | 21,729 |  |  |  | 71,509 |  |  |  | 63,689 |
Net sales |  | $ | 111,708 |  |  | $ | 105,247 |  |  | $ | 331,964 |  |  | $ | 316,927 |

X
- Definition Non GAAP net margin by segment reporting. + References No definition available. + Details
Name: | ofix_NonGAAPNetMarginBySegmentReportingTableTextBlock
Namespace Prefix: | ofix_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenues by reporting segment. + References No definition available. + Details
Name: | ofix_ScheduleOfSegmentReportingRevenuesBySegmentTableTextBlock
Namespace Prefix: | ofix_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration